U.O.C. Clinica Medica e Malattie Vascolari, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo F. Vito 1, 00168, Rome, Italy.
Laboratory of Vascular Biology and Genetics, Università Cattolica del Sacro Cuore, Rome, Italy.
Cardiovasc Diabetol. 2019 Jan 11;18(1):5. doi: 10.1186/s12933-019-0805-5.
Sortilin is a 95-kDa protein which has recently been linked to circulating cholesterol concentration and lifetime risk of developing significant atherosclerotic disease. Sortilin is found inside different cell types and circulating in blood. Higher circulating sortilin concentration has been found in patients with coronary atherosclerosis compared to control subjects. Sortilin concentration is influenced by statin therapy.
We enrolled statin-naïve subjects with type 2 diabetes mellitus and we performed a cross-sectional study to evaluate the association between sortilin levels and the presence of clinically significant lower limb peripheral artery disease (PAD) in a population of statin-free diabetic subjects.
Out of the 154 patients enrolled in our study, 80 patients were free from PAD, while 74 had clinically significant PAD. Sortilin concentration was significantly higher in the latter group compared to the former (1.61 ± 0.54 ng/mL versus 0.67 ± 0.30 ng/mL, P < 0.01) and there was a trend toward increased sortilin levels as disease severity increased. The association of sortilin levels with PAD remained after adjusting for major risk factors in a multivariate analysis.
We showed that sortilin is significantly and independently associated with the presence of lower limb PAD in a statin-free diabetic population and it may be a promising marker for clinically significant atherosclerosis of the lower limbs. Further studies are needed to confirm this finding and to evaluate its clinical usefulness.
Sortilin 是一种 95kDa 的蛋白质,它与循环胆固醇浓度和发生严重动脉粥样硬化疾病的终生风险有关。Sortilin 存在于不同的细胞类型中,并在血液中循环。与对照组相比,患有冠状动脉粥样硬化的患者的循环 Sortilin 浓度更高。Sortilin 浓度受他汀类药物治疗的影响。
我们招募了他汀类药物初治的 2 型糖尿病患者,并进行了一项横断面研究,以评估他汀类药物治疗患者的 Sortilin 水平与临床显著下肢外周动脉疾病(PAD)之间的关系。
在我们研究的 154 名患者中,80 名患者无 PAD,而 74 名患者有临床显著 PAD。后者组的 Sortilin 浓度明显高于前者(1.61±0.54ng/mL 与 0.67±0.30ng/mL,P<0.01),并且随着疾病严重程度的增加,Sortilin 水平呈上升趋势。多元分析调整主要危险因素后,Sortilin 水平与 PAD 的相关性仍然存在。
我们表明,在他汀类药物治疗患者中,Sortilin 与下肢 PAD 的存在显著独立相关,它可能是下肢严重动脉粥样硬化的有前途的标志物。需要进一步的研究来证实这一发现,并评估其临床应用价值。